Please make a donation to the Aplastic Anemia and MDS International Foundation.
Donate Today
Luspatercept generated favorable efficacy and safety outcomes in the treatment of anemia in patients with transfusion-dependent, lower-risk MDS. Data from a systematic review and meta-analysis of 20 studies demonstrated that luspatercept-aamt (Reblozyl) yielded high red blood…
Key Points MRD-guided azacitidine therapy can effectively prevent or delay relapse in MDS/AML. Over half of initial responders stayed relapse-free for ≥2 years after treatment. Abstract Measurable residual disease (MRD) can predict relapse in patients with advanced…
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) remains monotherapy with a hypomethylating agent (HMA), including azacitidine, decitabine, or oral decitabine/cedazuridine. Many attempts…
Akriti G Jain, MD treats myeloid disorders at Cleveland Clinic’s Main Campus in Cleveland, Ohio. She has a personal interest in taking care of patients with Myeloproliferative Neoplasms including Chronic Myeloid Leukemia. Her passion lies in understanding the needs of every patient and always prioritizing and advocating for her patients and their families. Her patient care philosophy involves offering in-depth explanation regarding diagnoses and to engage in active partnership with her patients and their referring providers to personalize decision-making and monitoring given the nature of the
Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital. He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS. Dr. Shallis also maintains
Abstract QuANTUM-First was a randomized trial that demonstrated that the addition of quizartinib, a potent and selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, to induction and consolidation chemotherapy, followed by monotherapy maintenance, improved the survival for…
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2…
Abstract Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potential curative therapy for myelodysplastic syndrome (MDS), recommended in higher risk disease according to the International Prognostic Scoring System (IPSS). We conducted a phase 2…
